

Revision date: 17-Jan-2007 Version: 1.1 Page 1 of 6

### 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

**Material Name: Ethacrynic Acid Tablets** 

Trade Name: Reomax Chemical Family: Mixture

Intended Use: Pharmaceutical product used as diuretic.

### 2. COMPOSITION/INFORMATION ON INGREDIENTS

#### **Hazardous**

Ingredient	CAS Number	<b>EU EINECS List</b>	%
Ethacrynic Acid	58-54-8	200-384-1	33
Starch	9005-25-8	232-679-6	*
Magnesium stearate	557-04-0	209-150-3	*

Ingredient	CAS Number	<b>EU EINECS List</b>	%
Lactose	63-42-3	200-559-2	*

Additional Information: \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

satety.

## 3. HAZARDS IDENTIFICATION

Appearance: Tablets
Signal Word: WARNING

Statement of Hazard: Harmful if swallowed.

**Additional Hazard Information:** 

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver

(based on components).

Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include loss of appetite

(anorexia), abdominal pain, changes in electrolytes, inability to swallow (dysphagia), nausea, vomiting, thirst, diarrhea. Clinical use has resulted in liver effects. Symptoms may include jaundice, liver function test abnormalities, and hepatitis. May cause adverse effects on the kidney. Other less common effects include allergic reaction, effects on hearing, vision.

Drowsiness, fatigue, or headache are also possible.

EU Indication of danger: Harmful

**EU Hazard Symbols:** 

Material Name: Ethacrynic Acid Tablets Page 2 of 6
Revision date: 17-Jan-2007 Version: 1.1



**EU Risk Phrases:** 

**Australian Hazard Classification** 

(NOHSC):

R22 - Harmful if swallowed.

Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

4. FIRST AID MEASURES

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical

attention.

**Skin Contact:** Wash exposed area with soap and water, remove contaminated clothing and obtain medical

assistance if irritation occurs. This material may not be completely removed by conventional

laundering. Consult professional laundry service. Do not home launder.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride,

and other chlorine-containing compounds.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

**Measures for Environmental** 

**Protections:** 

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

Material Name: Ethacrynic Acid Tablets

Page 3 of 6
Revision date: 17-Jan-2007

Version: 1.1

# 7. HANDLING AND STORAGE

General Handling: Avoid generating airborne dust. If tablets or capsules are crushed and/or broken, avoid

breathing dust and avoid contact with eyes.

**Storage Conditions:** Store as directed by product packaging.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Starch

**OSHA - Final PELS - TWAs:** = 15 mg/m<sup>3</sup> TWA total

= 5 mg/m<sup>3</sup> TWA

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA Australia TWA = 10 mg/m³ TWA

Magnesium stearate

**ACGIH Threshold Limit Value (TWA)** = 10 mg/m³ TWA except stearates of toxic metals

Australia TWA = 10 mg/m<sup>3</sup> TWA

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures.

**Personal Protective Equipment:** 

Hands: Not required for the normal use of this product. Wear protective gloves when working with

large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is

possible.

**Skin:** Not required for the normal use of this product. Wear protective clothing when working with

large quantities.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit

(OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control

exposures to below the OEL.

# 9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:TabletsColor:Not applicableMolecular Formula:MixtureMolecular Weight:Mixture

# 10. STABILITY AND REACTIVITY

**Stability:** Stable under normal conditions of use. **Conditions to Avoid:** None for the normal use of this material

**Incompatible Materials:** Incompatible with acids.

### 11. TOXICOLOGICAL INFORMATION

**General Information:** The information in this section describes the potential hazards of the individual ingredients and

the formulation.

### **Product Level Toxicity Data**

Material Name: Ethacrynic Acid Tablets

Page 4 of 6
Revision date: 17-Jan-2007

Version: 1.1

**Repeated Dose Toxicity** 

DurationSpeciesRouteDose (mg/kg/day)End PointTarget Organ(s)6 Month(s)MouseOral10 mg/kgNOAELNone identified

### **Ingredients:**

### Acute Toxicity: (Species, Route, End Point, Dose)

#### **Ethacrynic Acid**

 Mouse
 Oral
 LD 50
 627 mg/kg

 Rat
 Oral
 LD 50
 1000 mg/kg

 Mouse
 IV
 LD50
 175 mg/kg

 Rat
 IP
 LD50
 43 mg/kg

Guinea pig Intravenous Maximally Symptomatic Dose 80 mg/kg

#### Lactose

Rat Oral LD50 > 10 g/kg

#### Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m<sup>3</sup>

#### Starch

Mouse IP LD50 6600 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

**Ethacrynic Acid** 

21 Day(s) Mouse Oral 100 mg/kg/day LOAEL Liver

### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

#### **Ethacrynic Acid**

Embryo / Fetal Development Rat No route specified 100 mg/kg NOAEL Not teratogenic

Fertility and Embryonic Development Rat No route specified 20 mg/kg/day NOAEL No effects at maximum dose Fertility and Embryonic Development Dog No route specified 5 mg/kg/day NOAEL No effects at maximum dose

### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### **Ethacrynic Acid**

79 Week(s) Rat No route specified 45 times human dose NOAEL Not carcinogenic

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be

avoided.

Page 5 of 6

Material Name: Ethacrynic Acid Tablets

Revision date: 17-Jan-2007 Version: 1.1

# 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

# 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# 15. REGULATORY INFORMATION

EU Symbol: Xn EU Indication of danger: Harmful

**EU Risk Phrases:** 

R22 - Harmful if swallowed.

**EU Safety Phrases:** 

S36/37 - Wear suitable protective clothing and gloves.

**OSHA Label:** 

**WARNING** 

Harmful if swallowed.

### Canada - WHMIS: Classifications

# WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

#### **Ingredients:**

**Ethacrynic Acid** 

Australia (AICS): Present
Standard for the Uniform Scheduling Schedule 4

for Drugs and Poisons:

EU EINECS List 200-384-1

Material Name: Ethacrynic Acid Tablets

Revision date: 17-Jan-2007

Page 6 of 6

Version: 1.1

Starch

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-679-6

Lactose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS List

200-559-2

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentEU EINECS List209-150-3

# 16. OTHER INFORMATION

Reasons for Revision: Updated Section 10 - Stability and Reactivity.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

**End of Safety Data Sheet**